Oleh Yadlovskyi

Oleh Yadlovskyi

Auto-generated profile, based on publicly available information

Oleh Yadlovskyi

Institute of Pharmacology and Toxicology, National Academy of Medical Sciences, Anton Tsedik 14, 03057 Kyiv, Ukraine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

3 June 2020 in Pharmacology and Drug Toxicology
Verified
Journal Article
Open access
PDF file
SDSergii Demchenko
Sergii Demchenko
OYO. E. Yadlovskyi
O. E. Yadlovskyi
OYO. V. Yudina
O. V. Yudina
ITI. I. Tubaltseva
I. I. Tubaltseva
YFYu. A. Fedchenkova
Yu. A. Fedchenkova
SDSergii Demchenko
Sergii Demchenko
Anxiety disorders are a widespread and growing problem of healthcare across the world. According to WHO data, neurosis and psychopaties are observed in 5–15 % of world population. In developed countries, about 20 % of population take anxiolytics permanently, and 30 % periodically. According to the WHO data it should be noted, that those pathologies affect different segments of population, from pediatric to geriatric population. Therapy of such nosologies imposes great loses on both individuals and society. 3-(41-Methoxyphenyl)-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine-3-yl-methyl)-аmine was obtained by condensation of 2-methoxy-3,4,5,6-tetrahydro-7H-azepine with (4-methoxyphenylamino) acetic acid hydrazide and further cyclization of the intermediate product. 3-Aryl-1-(41-methoxyphenyl)1-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine-3-yl-methyl)-urea derivatives were obtained by condensation of 3-(41-methoxyphenyl)-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine-3-ylmethyl)-аmi ne with appropriate arylisocyanates in dry benzene medium. The aim of the study – to synthesize and study an anxiolytic activity of 3-aryl-1-(41-methoxyphenyl)1-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine-3-yl-methyl)-urea derivatives in comparison with known drugs diazepam and gidazepam on the stage of primary pharmacological screening. Tranquilizing activity of compounds was evaluated on models of «open field», «corazol convulsions» and «wire test» on mice, after administration at doses, equimolar to ED50 of diazepam. Diazepam (2 mg/kg) and gidazepam (2 mg/kg) were used as referent compounds. There were established, that 3-aryl-1-(41-methoxyphenyl)-1-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine-3-yl-methyl)-urea derivatives are characterized by anticonvulsant and anxiolytic activity. The absence of muscle relaxant effect and absence or moderate inhibition of horizontal activity, suggest the absence of GABAergic component in specific activity of studied compounds. Anticonvulsant and behavioral activity («open field») of studied compounds depend on modification of substitutes on para- and ortho- positions of benzene ring of N`-group of urea. By specific activity, researched compounds are not inferior (or exceed) daytime tranquilizer gidazepam. On open field model compound 1-(41-methoxyphenyl)-1-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a] azepin-3-yl-methyl)-3-(p-tolyl)-urea 5 d is characterized by lesser influence on horizontal, vertical and exploration activity, while grooming and quantity of feces droppings are significantly inhibited. This indicates less sedation in comparison to such of diazepam. However, on open field model compound 5 d exceeds daytime tranquilizer gidazepam by results of primary screening.

22 April 2021 in Farmatsevtychnyi zhurnal
Verified
Journal Article
Open access
PDF file
ОЯО. Є. Ядловський
О. Є. Ядловський
SDSergii Demchenko
Sergii Demchenko
ІКІ. І. Конвалюк
І. І. Конвалюк
ЛМЛ. П. Можилевська
Л. П. Можилевська
ОБО. А. Бєда
О. А. Бєда
СЯС. М. Ярмолюк
С. М. Ярмолюк
Several social, psychological and biological factors could be cause for central nervous system disorders, especially anxiety; the latter could lead to more serious neurological and psychosomatical disorders. Sedative medications of plant origin are widely used practically as an alternative and/or additive to traditional pharmacological treatments of anxiety, hyperexcitation and other neuroses. Thus, the search of new effective sedatives based on plant extracts is an actual and perspective task. Aim of the present work is to investigate the sedative effect of biomass extract from cell culture of Rauwolfia serpentina K-27 strain. Sedative action of biomass extract from cell culture of Rauwolfia serpentina high-productive strain was determined by open field method on 24 white mice males (no line). Mice weight was in 18–25 g interval. The behavior was assessed by usual behavioristic acts: motor activity, psychoemotional activity and tentative research reaction. Animals were randomized into 3 groups of 8 individuals each. Rauwolfia serpentina biomass extract at doses of 7.5 mg/kg (group 1) or 15 mg/kg (group 2) was administered orally as an aqueous solution. Animals of the control group (group 3) received a solvent (distilled water). The sedative effect of extract was discovered in doses of 7.5 and 15 mg/kg, that showed a decrease in horizontal motor activity to 63.31 and 79.76% respectively, vertical activity to 82.05 and 71.79%, grooming duration to 57.28 and 60.78% at experimental days 20 to 28. Tentative research reaction demonstrated the direct dependence of sedation intensity on duration of extract administration. As a result of the conducted researches significant differences in the number of fecal bolus of both experimental and control groups of mice were not revealed. No significant difference between the sedative effect and the dose (7.5 and 15 mg/kg) was observed. The sedative effect of biomass extract from cell culture of Rauwolfia serpentina K-27 strain was proven. This leads to perspective inclusion of the extract to traditional medicine in prophylaxis and treatment of insomnia and of physical and psychological overexcitation.

2 July 2024 in Український радіологічний та онкологічний журнал
Verified
Journal Article
Open access
NUN.YE. Uzlenkova
N.YE. Uzlenkova
AGA.S. Grygoryeva
A.S. Grygoryeva
NSN.G. Skorobogatova
N.G. Skorobogatova
АKА.I. Kryvko
А.I. Kryvko
ILI.O. Leonova
I.O. Leonova
OYO.YE. Yadlovsky
O.YE. Yadlovsky
Background. The targeted search for new effective radioprotective agents, especially among compounds with antioxidant properties, remains relevant. Among them, quercetin which has a high specific activity against oxidative stress (cited as a «universal antioxidant») deserves attention. The transport liposomal composition of quercetin, which significantly improves its bioavailability and is the basis of the licensed drug «Lipoflavon®» (LF), is known, but the radioprotective properties of this drug have not been studied. The purpose of the work is to position Lipoflavon as a radioprotector for the first time based on the study of radioprotective activity in an acute experiment with total irradiation of rats. Materials and methods. The rat model of acute radiation syndrome (ARS) was carried out by short-term bilateral total body irradiation (TBI) on a CLINAC (6 MeV) linear accelerator at doses of 5.5 and 7.0 Gy. The control rats were sham-irradiated. The test sample of LF was used for the studies. LF (1.5 mg/mL) was administered to rats 30 min before TBI through the tail vein. The control TBI rats were injected with physiological saline. Experimental rats were randomly assigned into groups as follows: group 1 – non-irradiated control (intact animals); group 2 – irradiated control at a dose of 5.5 Gy (TBI5.5); group 3 – irradiation at a dose of 5.5 Gy with administration of LF (LF + TBI5.5); group 4 – irradiated control at a dose of 7.0 Gy (TBI7.0); group 5 – irradiation at a dose of 7.0 Gy with administration of LF (LF + TBI7.0). Clinical characteristics of ARS, overall survival, and the mean survival time of the dead animals were determined. The profiles of lethality («peaks of death») were calculated as total rat lethality (%) in certain time periods of the ARS. In hematological studies, LF was administered 24 h prior to TBI and twice a week the next 4 weeks after TBI. The hematological parameters were monitored on days 3, 7, 14 and 21 after TBI. Results. It was established that prophylactic LF administered 30 min before TBI at doses of 5.5 and 7.0 Gy, which were LD20/30 and DL73.3/30, increased the 30-day survival rate of the irradiated rats to 90 and 40% respectively, compared to 80 and 26.7% in irradiated control, and changed the radiation lethality profile of the rats in the model of ARS. The radioprotective activity of LF manifested in the form of the absence of early and late peaks of death of the irradiated rats and the survival time of more than 30 days after the treatment in 40% of rats with LD73,3/30. Prophylactic and therapeutic administration of LF prevented development of severe leukopenia and thrombocytopenia and contributed to a more rapid and sustained recovery of erythrocytes during the period of ARS. The most efficient radioprotective therapeutic effect of LF was observed in rats with a dose of LD73.3/30. Conclusions. The results of the study substantiate the radioprotective activity of Lipoflavon in ARS and help develop the new approaches to using the licensed drug «Lipoflavon®» as an effective pharmacological therapeutic agent for radiation protection in acute radiation.

30 September 2026 in Current Bioactive Compounds
Verified
Journal Article
Closed access
PDF file
SDSergii Demchenko
Sergii Demchenko
AMArtur Martynov
Artur Martynov
Volodymyr ZaitsevVolodymyr Zaitsev
Volodymyr Zaitsev
YNYevhenii Novodvorskyi
Yevhenii Novodvorskyi
OYOleh Yadlovskyi
Oleh Yadlovskyi
IIIvan Iurchenko
Ivan Iurchenko
Introduction: Epilepsy is a major global health burden, affecting more than 70 million people worldwide. Approximately 20-30% of patients do not achieve adequate seizure control with currently available antiseizure medications. This study investigates novel triazin-5-one derivatives as potential antiseizure agents targeting the γ-aminobutyric acid (GABA) system. The compounds were designed to interact with GABAA receptors and inhibit GABA aminotransferase (GABA-AT), using lamotrigine as a reference antiseizure drug. This dual-target strategy may support the development of more effective therapies for drug-resistant epilepsy. Materials and Methods: Eighteen 6-(4-methoxybenzyl)-3-R-4H-[1,2,4]triazin-5-one derivatives (3a–r) were synthesized and characterized by 1H and 13C NMR spectroscopy, LC-MS, and elemental analysis. Molecular docking was performed against the GABAA receptor (PDB ID: 1OHV) and GABA-AT enzyme (PDB ID: 1SF2) to estimate binding affinity. GABA-AT inhibition was evaluated in vitro, and anticonvulsant activity was assessed in mouse models at doses equimolar to 10 mg/kg lamotrigine. Results: Compounds 3o, 3f, 3r, 3g, and 3h showed the highest predicted binding affinities for the GABAA receptor, with binding-energy magnitudes exceeding 10 kcal/mol. Compound 3h (3-(2,3-dimethylphenylamino)-6-(4-methoxybenzyl)-4H-[1,2,4]triazin-5-one) exhibited the lowest IC50 value for GABA-AT inhibition (30.50 ± 0.61 μM), comparable to that of lamotrigine (32.7 ± 0.7 μM). In the animal model, compounds 3f and 3h completely suppressed clonic and recurrent clonic-tonic seizures. Docking analysis indicated that 3h forms hydrogen bonds with Arg430 and Ile426 through the triazine oxygen atom and interacts with His44 through a triazine nitrogen atom. Discussion: The anticonvulsant effects of these 1,2,4-triazine derivatives appear to depend on the substituents at positions 3 and 6 of the heterocyclic ring. Their potential dual mechanism, involving both receptor modulation and enzyme inhibition, may contribute to their neurotropic activity. Compound 3r contains a defined pharmacophore incorporating tryptamine and triazine fragments, whereas the spatial requirements underlying the activity of compound 3h remain unclear and require further structural investigation. Conclusion: The study identifies novel triazin-5-ones, specifically compounds 3h and 3f, as promising candidates for the development of new antiseizure therapies. These derivatives demonstrate potency and efficacy comparable to lamotrigine and may offer a multi-target mechanism within the GABAergic system.

4 December 2025 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
SDSergii Demchenko
Sergii Demchenko
AMArtur Martynov
Artur Martynov
YNYevhenii Novodvorskyi
Yevhenii Novodvorskyi
OYOleh Yadlovskyi
Oleh Yadlovskyi
OMOleh Moskalenko
Oleh Moskalenko
SYSergiy Yarmoluk
Sergiy Yarmoluk